Repaglinide - A new compound for the treatment of patients with type 2 diabetes

Netherlands Journal of Medicine

Volumn 55, Issue 5, 1999, Pages 229-234

  Wolffenbuttel, Bruce H R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trial; Hypoglycaemia; Insulin secretagogue; Repaglinide; Treatment; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; METFORMIN; PLACEBO; POTASSIUM CHANNEL; REPAGLINIDE; SULFONYLUREA;

ARTICLE; BINDING SITE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RESPIRATORY TRACT DISEASE;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; FOOD HABITS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; PIPERIDINES;

EID: 0032692543     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00068-6     Document Type: Article

References (14)

1. DeFronzo R.A. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 37:1988;667-687.
2. Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet. 343:1994;91-95.
3. Polonsky K.S., Given B.D., Hirsch L.J., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 318:1988;1231-1239.
4. Wolffenbuttel B.H.R., Graal M.B. New treatment for patients with type 2 diabetes mellitus. Postgrad Med J. 72:1996;657-672.
5. Yki-Jarvinen H. Glucose toxicity. Endocrine Rev. 13:1992;415-431.
6. Stenman S., Melander A., Groop P.H., Groop L.C. What is the benefit of increasing the sulfonylurea dose? Ann Int Med. 118:1993;169-172.
7. Groop L.C., Luzi L., DeFronzo R.A., Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet. ii:1989;129-130.
8. Lebovitz H.E., Melander A. Sulfonylureas: Basic aspects and clinical uses. Alberti K.G.M.M. DeFronzo R.A., Keen H., Zimmet P. International Textbook of Diabetes Mellitus. 1992;John Wiley and Sons.
9. Asplund K., Wiholm B.-E., Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 24:1983;412-417.
10. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 343:1994;95-100.
11. Wolffenbuttel B.H.R., Nijst L., Sels J.P., Menheere P.P.C.A., Muller P.G., Nieuwenhuijzen Kruseman A.C. Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulfonylurea-treated patients with NIDDM. Eur J Clin Pharmacol. 45:1993;113-116.
12. Tronier B., Marbury T.C., Damsbo P., Windfeld K. A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well controlled NIDDM patients. Diabetologia. 38:(Suppl. 1):1995;A195.
13. Moses R., Slobodniuk R., Boyages S., Colagiuri S., Kidson W., Carter J., et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 22:1999;119-124.
14. Wolffenbuttel B.H.R., Landgraf R. A one-year multicenter, randomized and double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes mellitus. Diabetes Care. 22:1999;463-467.